Wednesday, August 21 | 14:00 CST / 15:00 JST
Transmembrane proteins (TPs) serve as crucial conduits between the internal and external environments of cells, regulating ion and molecule passage and orchestrating cellular responses to external cues. They play pivotal roles in cellular signaling, cell-cell interactions, and various physiological processes, making them promising targets for novel therapeutics, including cell and gene therapies. Leveraging the unique properties of TPs, researchers can design targeted therapeutic strategies with improved efficacy, specificity, and safety profiles.
However, isolating biologically relevant forms of TPs, particularly multi-pass TPs, presents formidable challenges due to their intricate structures and limited expression levels. Addressing this demand, ACROBiosystems has pioneered cutting-edge technology platforms tailored to the complexities of multi-pass TPs. This innovation has yielded a comprehensive suite of full-length, stabilized multi-pass TPs, including key therapeutic targets such as CD20, Claudin18.2, CD133, and others. Engineered to maintain native folding and high activity, these proteins serve as invaluable tools for advancing drug development and uncovering novel mechanisms of action.
In collaboration with Nicoya, a cutting-edge technology company dedicated to supporting drug development through advanced analytical solutions, Nicoya’s Alto™ digital surface plasmon resonance (SPR) system was utilized to characterize the binding kinetics of several transmembrane proteins in detergent, nanodisc, and virus-like particle (VLP) formats. This webinar will showcase how the Alto digital SPR system provides high-quality data on challenging membrane protein candidates while significantly reducing sample consumption and time to results. Through this collaboration, researchers and pharmaceutical developers gain access to advanced technologies that enable the production, stabilization and precise characterization of challenging transmembrane protein interactions, accelerating the development of novel therapeutics and unlocking new frontiers in therapeutic targeting.
What you'll learn
- Discover Nicoya’s cutting-edge digital SPR platform Alto™, which is revolutionizing the analytical development of biologically relevant multi-pass transmembrane proteins and overcoming industry challenges.
- Learn about ACROBiosystems' dynamic suite of stabilized multi-pass TPs, featuring key therapeutic targets like CD20, Claudin18.2, CD133, and more.
- Gain insights into the potential of leveraging Alto digital SPR and ACROBiosystems transmembrane proteins for developing novel therapeutics for cellular and genetic disorders.
Upcoming webinar
Label-free characterization of challenging transmembrane proteins using Alto digital SPR
Low sample consumption
Get full kinetics and
affinity data with only 2 μL of sample
Simplified workflow
Consolidate all analyses
to a single cartridge
Automated assays
Leverage automated assays that reduce time, effort, and cost
ANALYSIS METHOD
Filter libraries based on binding rate and response.
HEAT MAP
See a visual overview of bind/ not-bind status.
GROUP BY
Filter ‘Bind’ candidates for viewing in a sensorgram.
DO NOT INCLUDE
Exclude erroneous data.
CAROUSEL VIEW
Efficiently navigate to the interaction of your choice.
Key features
Crude sample and serum compatibility, low sample volumes, automated assays, and intuitive software make binding characterization easy. Powered by digital microfluidics, Alto is the world’s most user-friendly SPR system — supporting binding kinetics, screening, epitope binning, and quantitation all within a compact, affordable system with a low cost per test.
Upcoming webinar
MLabel-free characterization of challenging transmembrane proteins using Alto digital SPR
Transmembrane proteins (TPs) serve as crucial conduits between the internal and external environments of cells, regulating ion and molecule passage and orchestrating cellular responses to external cues. They play pivotal roles in cellular signaling, cell-cell interactions, and various physiological processes, making them promising targets for novel therapeutics, including cell and gene therapies. Leveraging the unique properties of TPs, researchers can design targeted therapeutic strategies with improved efficacy, specificity, and safety profiles.
However, isolating biologically relevant forms of TPs, particularly multi-pass TPs, presents formidable challenges due to their intricate structures and limited expression levels. Addressing this demand, ACROBiosystems has pioneered cutting-edge technology platforms tailored to the complexities of multi-pass TPs. This innovation has yielded a comprehensive suite of full-length, stabilized multi-pass TPs, including key therapeutic targets such as CD20, Claudin18.2, CD133, and others. Engineered to maintain native folding and high activity, these proteins serve as invaluable tools for advancing drug development and uncovering novel mechanisms of action.
In collaboration with Nicoya, a cutting-edge technology company dedicated to supporting drug development through advanced analytical solutions, Nicoya’s Alto™ digital surface plasmon resonance (SPR) system was utilized to characterize the binding kinetics of several transmembrane proteins in detergent, nanodisc, and virus-like particle (VLP) formats. This webinar will showcase how the Alto digital SPR system provides high-quality data on challenging membrane protein candidates while significantly reducing sample consumption and time to results. Through this collaboration, researchers and pharmaceutical developers gain access to advanced technologies that enable the production, stabilization and precise characterization of challenging transmembrane protein interactions, accelerating the development of novel therapeutics and unlocking new frontiers in therapeutic targeting.
What you'll learn
- Discover Nicoya’s cutting-edge digital SPR platform Alto™, which is revolutionizing the analytical development of biologically relevant multi-pass transmembrane proteins and overcoming industry challenges.
- Learn about ACROBiosystems' dynamic suite of stabilized multi-pass TPs, featuring key therapeutic targets like CD20, Claudin18.2, CD133, and more.
- Gain insights into the potential of leveraging Alto digital SPR and ACROBiosystems transmembrane proteins for developing novel therapeutics for cellular and genetic disorders.
- How to optimize experimental conditions including ligand density, analyte concentration range, choosing an appropriate buffer, and more
Speakers
- Mike Piazza, PhD, Director of Applications Development, Nicoya Lifesciences
- Anil Kumar, PhD, Head of CMC in Europe, ACROBiosystems Group
- Qinan Zhuang, Sales Director, APAC, Nicoya Lifesciences
- Han Su, PhD, Field Applications Scientist, Nicoya Lifesciences
Register now
Ready to accelerate your biologics discovery with Alto?
Download our Alto brochure to learn more.
Meet Alto
Speakers
- Mike Piazza, PhD, Director of Applications Development, Nicoya Lifesciences
- Anil Kumar, PhD, Head of CMC in Europe, ACROBiosystems Group
- Qinan Zhuang, Sales Director, APAC, Nicoya Lifesciences
- Han Su, PhD, Field Applications Scientist, Nicoya Lifesciences